Inactive Instrument

Mirati Therapeutics

MRTX

US60468T1051

Presentation Operator MessageOperator (Operator)Welcome to the Mirati Therapeutics 2019 Annual...

This article is reserved for subscribers

Signed up already?

Not subscribed yet?

Latest news about Mirati Therapeutics

British billionaire Joe Lewis intends to plead guilty to US charges, lawyer says	24/01	RE
Mirati Therapeutics, Inc.(NasdaqGS:MRTX) dropped from S&P Biotechnology Select Industry Index	24/01	CI
Mirati Therapeutics, Inc.(NasdaqGS:MRTX) dropped from S&P TMI Index	24/01	CI
Mirati Therapeutics, Inc.(NasdaqGS:MRTX) dropped from S&P Global BMI Index	24/01	CI
Bristol-Myers Squibb Closes Acquisition of Mirati Therapeutics	24/01	MT
Bristol-Myers Squibb Closes Mirati Therapeutics Acquisition	23/01	MT
Bristol Myers: acquisition of Mirati Therapeutics finalized	23/01	CF
Mirati Therapeutics, Inc. Announces Management Changes	23/01	CI
Mirati Therapeutics, Inc.(NasdaqGM:MRTX) dropped from NASDAQ Composite Index	23/01	CI
Bristol-Myers Squibb Company completed the acquisition of Mirati Therapeutics, Inc. from a group of shareholders.	23/01	CI
Mirati Therapeutics, Inc.(NasdaqGS:MRTX) dropped from NASDAQ Biotechnology Index	22/01	CI
Mirati Therapeutics' Krazati Lung Cancer Treatment Gets EU Conditional Marketing Authorization	10/01	MT
Bristol Myers expects to launch 16 new products through 2030 - CEO	08/01	RE
Immunome Appoints Phil Roberts as Chief Technical Officer	04/01	MT
US FDA turns down Amgen lung cancer drug Lumakras for full approval	26/12	RE
Bristol-Myers Agrees Deal to Buy RayzeBio for About $4.1 Billion	26/12	MT
Bristol-Myers Squibb Strikes $14 Billion Deal to Acquire Karuna Therapeutics	22/12	MT
North American Morning Briefing : Stock Futures -2-	21/12	DJ
Citigroup Downgrades Mirati Therapeutics to Neutral From Buy, Raises Price Target to $59 From $48	20/12	MT
Mirati Therapeutics, Inc. Receives Positive Opinion from CHMP for KRAZATI as a Targeted Treatment Option for Patients with Advanced Non-Small Cell Lung Cancer with a KRASG12C Mutation Following a Re-Examination Procedure	10/11	CI
North American Morning Briefing : Stock Futures -2-	08/11	DJ
Stifel Downgrades Mirati Therapeutics to Hold From Buy, Cuts Price Target to $59 From $83	07/11	MT
Earnings Flash (MRTX) MIRATI THERAPEUTICS Posts Q3 Revenue $16.4M	06/11	MT
Mirati Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	06/11	CI
Sector Update: Health Care Stocks Rising Late Afternoon	03/11	MT

Mirati Therapeutics, Inc. is a commercial-stage oncology company. The Company is developing novel therapeutics to address the genetic and immunological promoters of cancer. The Company's product KRAZATI is an oral targeted treatment option for adult patients with KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC). Its MRTX1133 is an investigational, selective, and potent KRAS G12D inhibitor. Its MRTX1719 is an investigational synthetic lethal PRMT5 inhibitor designed to specifically target the PRMT5/ methylthioadensoine (MTA) complex. Its MRTX0902 is a potent, selective SOS1 inhibitor, designed to improve anti-tumor efficacy in combination with targeted mitogen-activated protein kinase (MAPK)-pathway inhibitors. Its Sitravatinib is an investigational spectrum-selective kinase inhibitor designed to potently inhibit receptor tyrosine kinases (RTKs) and enhance immune responses through the inhibition of immunosuppressive signaling.

Sector

More about the company

Mirati Therapeutics

Equities

MRTX

US60468T1051

Latest news about Mirati Therapeutics

Chart Mirati Therapeutics

Company Profile